drugset / Trial / NCT05122780

Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial).

NCT05122780

RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of our study is to evaluate if the use of a precision-medicine approach with a specific therapy tailored on the underlying pathogenic mechanism will improve the quality-of-life in MINOCA patients. The investigators further aim at investigating wherever a precision-medicine approach will improve the prognosis, healthcare related costs, and if that a different profile of plasma biomarkers and microRNAs may serve as diagnostic tools for detecting specific causes of MINOCA and to assess response to therapy. Finally, beyond its pivotal role in differential diagnosis, the investigators hypothesize that cardiac magnetic resonance (CMR) may provide a morphological and functional cardiac characterization as well as help in the prognostic stratification.

Timeline

Start
2021-07-01
Primary completion
2025-07
Completion
2025-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Diltiazem Small molecule
Comparator Warfarin Small molecule
Comparator nitroglycerine Unknown
Background Aspirin Small molecule 75 mg Intravenous
Background Atorvastatin Small molecule
Background Bisoprolol Other / unclassified
Background Clopidogrel Small molecule 75 mg Oral
Background Ramipril Small molecule

Indications